Key Research Statistics
Systemic Tissue Repair
61%Faster Re-epithelializationWound closure at 7 days vs untreated control
>50%Cardiac LV RecoveryLeft ventricular function improvement post-infarction
0Serious Adverse EventsPhase 1 trial: 42–1,260 mg IV over 14 days
170+Cited Studies43-amino acid endogenous peptide — strong evidence base
Response Rates by Tissue Type
Systemic delivery — works body-wide
Athletic Recovery95%
Muscle Soreness90%
Tendon/Ligament85%
Chronic Muscle80%
Cardiac/Systemic70%
Clinical + practitioner data
TB-500 at the Cellular Level
Thymosin beta-4 fragment

TB-500 in the Body
Thymosin Beta-4 active fragment

Complete Your Protocol
Complementary compounds from other research areas






